These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28242811)

  • 1. Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer.
    Mustachio LM; Lu Y; Tafe LJ; Memoli V; Rodriguez-Canales J; Mino B; Villalobos PA; Wistuba I; Katayama H; Hanash SM; Roszik J; Kawakami M; Cho KJ; Hancock JF; Chinyengetere F; Hu S; Liu X; Freemantle SJ; Dmitrovsky E
    Mol Cancer Res; 2017 Jul; 15(7):905-914. PubMed ID: 28242811
    [No Abstract]   [Full Text] [Related]  

  • 2. The ISG15-specific protease USP18 regulates stability of PTEN.
    Mustachio LM; Kawakami M; Lu Y; Rodriguez-Canales J; Mino B; Behrens C; Wistuba I; Bota-Rabassedas N; Yu J; Lee JJ; Roszik J; Zheng L; Liu X; Freemantle SJ; Dmitrovsky E
    Oncotarget; 2017 Jan; 8(1):3-14. PubMed ID: 27980214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis.
    Chen Z; Zheng L; Chen Y; Liu X; Kawakami M; Mustachio LM; Roszik J; Ferry-Galow KV; Parchment RE; Liu X; Andresson T; Duncan G; Kurie JM; Rodriguez-Canales J; Liu X; Dmitrovsky E
    Cancer Biol Ther; 2022 Dec; 23(1):265-280. PubMed ID: 35387560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.
    Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Yamada G; Hasegawa T; Miyagi Y; Niki T; Watanabe A; Takahashi H; Sakuma Y
    Int J Oncol; 2018 Jul; 53(1):33-46. PubMed ID: 29658609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target.
    Mustachio LM; Lu Y; Kawakami M; Roszik J; Freemantle SJ; Liu X; Dmitrovsky E
    Cancer Res; 2018 Feb; 78(3):587-592. PubMed ID: 29343520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Ubiquitin-Specific Peptidase USP18 Promotes Lipolysis, Fatty Acid Oxidation, and Lung Cancer Growth.
    Liu X; Lu Y; Chen Z; Liu X; Hu W; Zheng L; Chen Y; Kurie JM; Shi M; Mustachio LM; Adresson T; Fox S; Roszik J; Kawakami M; Freemantle SJ; Dmitrovsky E
    Mol Cancer Res; 2021 Apr; 19(4):667-677. PubMed ID: 33380466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for the ubiquitin protease UBP43 as an antineoplastic target.
    Guo Y; Chinyengetere F; Dolinko AV; Lopez-Aguiar A; Lu Y; Galimberti F; Ma T; Feng Q; Sekula D; Freemantle SJ; Andrew AS; Memoli V; Dmitrovsky E
    Mol Cancer Ther; 2012 Sep; 11(9):1968-77. PubMed ID: 22752428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.
    Baldelli E; Bellezza G; Haura EB; Crinó L; Cress WD; Deng J; Ludovini V; Sidoni A; Schabath MB; Puma F; Vannucci J; Siggillino A; Liotta LA; Petricoin EF; Pierobon M
    Oncotarget; 2015 Oct; 6(32):32368-79. PubMed ID: 26468985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
    Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
    Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
    Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
    Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.
    McCleland ML; Adler AS; Deming L; Cosino E; Lee L; Blackwood EM; Solon M; Tao J; Li L; Shames D; Jackson E; Forrest WF; Firestein R
    Clin Cancer Res; 2013 Feb; 19(4):773-84. PubMed ID: 23224736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous
    Meder L; Florin A; Ozretić L; Nill M; Koker M; Meemboor S; Radtke F; Diehl L; Ullrich RT; Odenthal M; Büttner R; Heukamp LC
    Pathol Oncol Res; 2021; 27():596522. PubMed ID: 34257546
    [No Abstract]   [Full Text] [Related]  

  • 14. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
    Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
    Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis.
    Schuster K; Venkateswaran N; Rabellino A; Girard L; Peña-Llopis S; Scaglioni PP
    Mol Cancer Res; 2014 Jun; 12(6):912-23. PubMed ID: 24618618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naproxen inhibits spontaneous lung adenocarcinoma formation in Kras
    Kumar G; Madka V; Singh A; Farooqui M; Stratton N; Lightfoot S; Mohammed A; Rao CV
    Neoplasia; 2021 Jun; 23(6):574-583. PubMed ID: 34091121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD44 promotes Kras-dependent lung adenocarcinoma.
    Zhao P; Damerow MS; Stern P; Liu AH; Sweet-Cordero A; Siziopikou K; Neilson JR; Sharp PA; Cheng C
    Oncogene; 2013 Oct; 32(43):5186-90. PubMed ID: 23208496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
    Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
    Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.
    Hill KS; Erdogan E; Khoor A; Walsh MP; Leitges M; Murray NR; Fields AP
    Oncogene; 2014 Apr; 33(16):2134-44. PubMed ID: 23604119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.